| name | endo-bariatric-eligibility |
| description | Determines if a patient is a candidate for bariatric surgery using BMI thresholds: BMI ≥35 kg/m2 with comorbidity or BMI ≥40 kg/m2 regardless of comorbidities. Triggers include when a clinician asks, 'Is this patient eligible for bariatric surgery given their BMI and comorbidities?' or 'Should I refer a patient with BMI 38 and sleep apnea for surgical evaluation?'. |
Assess bariatric surgery eligibility based on BMI/comorbidity
STEP 1 — Gather Information
Collect current BMI (kg/m2) and document presence of obesity‑related comorbidities such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, NAFLD, osteoarthritis, or cardiovascular disease.
STEP 2 — Rule In / Rule Out
Is BMI ≥40 kg/m2?
- Yes → Patient meets surgical threshold regardless of comorbidities; proceed to STEP 4.
- No → Proceed to STEP 3.
STEP 3 — Classify or Stratify
Is BMI between 35.0–39.9 kg/m2 and at least one comorbidity present?
- Yes → Patient meets surgical threshold with comorbidity; proceed to STEP 4.
- No → Patient does not meet surgical criteria; proceed to STEP 4 for alternative management.
STEP 4 — Decide
If criteria met (BMI ≥40, or BMI 35‑39.9 with comorbidity): refer for bariatric surgery evaluation and discuss risks/benefits.
If criteria not met: optimize lifestyle intervention, consider pharmacotherapy per guideline, and reassess in 3–6 months.
Clinical Guardrails / Mimics / Pitfalls
Do not base eligibility on BMI alone without verifying comorbidities; avoid referring patients with BMI 35‑39.9 lacking documented comorbidity; screen for contraindications (uncontrolled psychiatric illness, substance use, inability to adhere to postoperative follow‑up); ensure shared decision‑making and informed consent before referral.
Concrete Clinical Example
A 45‑year‑old with BMI 38 kg/m2 and documented obstructive sleep apnea presents for weight management. BMI is 35‑39.9 with a comorbidity → eligible for surgical referral; patient is counseled on surgery risks/benefits and scheduled for bariatric surgery evaluation.
Source: Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI: 10.1210/jc.2014-3415
